Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated With Ipilimumab

International Journal of Radiation Oncology Biology Physics

Volumn 96, Issue 1, 2016, Pages 72-77

  Qin, Rosie ^a   Olson, Adam ^b   Singh, Bhavana ^b   Thomas, Samantha ^b   Wolf, Steven ^b   Bhavsar, Nrupen A ^b   Hanks, Brent A ^b   Salama, Joseph K ^b   Salama, April K S ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATOLOGY; ONCOLOGY; PATIENT MONITORING; RADIOTHERAPY; TOXICITY; TUMORS;

CLINICAL INFORMATION; METHODS AND MATERIALS; OPTIMAL TIMING; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANK TEST; SURVIVAL RATE; TUMOR RESPONSE;

PATIENT TREATMENT;

IPILIMUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ADRENAL INSUFFICIENCY; ADULT; ADVANCED CANCER; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; BRAIN METASTASIS; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED ANEMIA; COHORT ANALYSIS; COLITIS; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DYSPNEA; ENDOCRINE DISEASE; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; HYPOPITUITARISM; HYPOTHYROIDISM; KIDNEY FAILURE; LEUKOPENIA; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; MEDICAL RECORD REVIEW; METASTATIC MELANOMA; MIDDLE AGED; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RADIATION DOSE FRACTIONATION; RASH; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VITILIGO; CONFORMAL RADIOTHERAPY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EPIDEMIOLOGY; MELANOMA; MORTALITY; NORTH CAROLINA; PREVALENCE; PROCEDURES; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDY; RISK FACTOR; SECONDARY; SURVIVAL RATE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; COHORT STUDIES; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; NORTH CAROLINA; PREVALENCE; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84978496382     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2016.04.017     Document Type: Article

References (14)

1. 1 Maio, M., Grob, J.J., Aamdal, S., et al. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol 33 (2015), 1191–1196.
2. 2 Schadendorf, D., Hodi, F.S., Robert, C., et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33 (2015), 1889–1894.
3. 3 Hodi, F.S., O'Day, S.J., McDermott, D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (2010), 711–723.
4. 4 Formenti, S.C., Demaria, S., Combining radiotherapy and cancer immunotherapy: A paradigm shift. J Natl Cancer Inst 105 (2013), 256–265.
5. 5 Finkelstein, S.E., Timmerman, R., McBride, W.H., et al. The confluence of stereotactic ablative radiotherapy and tumor immunology. Clin Dev Immunol, 2011, 2011, 439752.
6. 6 Demaria, S., Pilones, K.A., Formenti, S.C., et al. Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment. Oncoimmunology, 2, 2013, e23127.
7. 7 Zhang, B., Bowerman, N.A., Salama, J.K., et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med 204 (2007), 49–55.
8. 8 Lee, Y., Auh, S.L., Wang, Y., et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: Changing strategies for cancer treatment. Blood 114 (2009), 589–595.
9. 9 Olivier, K.R., Schild, S.E., Morris, C.G., et al. A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma. Cancer 110 (2007), 1791–1795.
10. 10 Dewan, M.Z., Galloway, A.E., Kawashima, N., et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 15 (2009), 5379–5388.
11. 11 Demaria, S., Kawashima, N., Yang, A.M., et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 11 (2005), 728–734.
12. 12 Barker, C.A., Postow, M.A., Khan, S.A., et al. Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res 1 (2013), 92–98.
13. 13 Salama, A.K., Postow, M.A., Salama, J.K., Irradiation and immunotherapy: From concept to the clinic. Cancer 122 (2016), 1659–1671.
14. 14 Formenti, S.C., Combining radiation therapy with immunotherapy: Clinical translation. J Transl Med, 13, 2015, 2048.